FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to a pharmaceutical composition for treating iron overload in powder form containing 25 wt. % to 45 wt. % of combination of lactose and sucrose with respect to total weight of powder and containing as an active ingredient from 35 wt. % to 40 wt. % of the compound represented by formula 1, or its pharmaceutically acceptable salt and from 0.2 wt. % to 10 wt. % of sodium lauryl sulphate with respect to total weight of powder. Invention also relates to a method for preparing a pharmaceutical composition in powder form.
[Formula 1].
EFFECT: technical result: obtaining a pharmaceutical composition in powder form, containing deferasirox as an active ingredient and low percentage content of additives, which can be taken without suspension in the aqueous phase, in addition, the obtained pharmaceutical composition exhibits high rate of dissolution.
12 cl, 7 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
| SODIUM IBUPROFEN TABLETS AND METHODS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING SODIUM IBUPROFEN | 2010 |
|
RU2715680C2 |
| COMPOSITION OF NANOSTRUCTURED APREPITANT, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2011 |
|
RU2595841C2 |
| COMPOSITIONS OF TELMISARTAN IN FORM OF NANOPARTICLES, AND METHOD FOR PREPARING THEM | 2010 |
|
RU2526914C2 |
| PHARMACEUTICAL PREPARATION IN TABLET FORM AND METHOD FOR ITS PREPARATION | 2019 |
|
RU2747525C2 |
| ABIRATERONE ACETATE FORMULATION | 2014 |
|
RU2732136C2 |
| PHARMACEUTICAL COMPOSITIONS OF MONTELUCAST AND LEVOCETIRISINE | 2013 |
|
RU2677649C2 |
| HEMFIBROZIL-CONTAINING PHARMACEUTICAL COMPOSITIONS | 1995 |
|
RU2152209C1 |
| COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | 2014 |
|
RU2683937C2 |
| BENZAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION ELICITING ENHANCED SOLUBILITY AND ABSORPTION CAPACITY IN ORAL APPLYING | 2000 |
|
RU2260428C2 |
